Latest News

Colonis Pharma Ltd Launches First Licensed Product

Colonis Pharma Ltd Launches First Licensed Product

Colonis Pharma Ltd, part of Quantum Pharma Plc, has entered the licensed pharmaceutical market with the launch of Aviticol™ (cholecalciferol 20 000 IU), for the treatment and prevention of vitamin D deficiency1
 
The launch of Aviticol™ coincides with recent recommendations made by the National Institute for Health and Care Excellence (NICE) concerning vitamin D supplement use among at-risk groups. These recommendations highlight the need for greater public awareness of vitamin D deficiency and for vitamin D supplements containing the recommended reference nutrient intake for at-risk groups to be available on prescription and listed in the British National Formulary2.
 
“Vitamin D deficiency is a major public health issue in the UK and one that is attracting considerable attention at the moment.  Moving into the licensed market with the launch of Aviticol™ for the treatment and prevention of vitamin D deficiency opens up many new opportunities for us,” explains Andy Scaife, Managing Director of Quantum Pharma Plc.
 
Aviticol™ can be prescribed in adults and children aged 12 years and over1.
 
 
 
Prescribing Information can be found here: https://www.medicines.org.uk/emc/medicine/29659
 
References
1. Aviticol 20 000 IU Capsules - Summary of Product Characteristics. December 2014.
2. National Institute for Health and Care Excellence (NICE). Public Health Guidance: Vitamin D: Increasing Supplement Use Among At-Risk Groups. November 2014.

 

Posted by: Quantum Webmaster on 18th December 2014